tiprankstipranks
Trending News
More News >
Krebs Biochemicals & Industries Ltd. (IN:KREBSBIO)
:KREBSBIO
India Market
Advertisement

Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis

Compare
0 Followers

Top Page

IN:KREBSBIO

Krebs Biochemicals & Industries Ltd.

(KREBSBIO)

Rating:39Underperform
Price Target:
₹71.00
▲(0.71% Upside)
Krebs Biochemicals & Industries Ltd. is facing substantial financial difficulties, with consistent losses and high leverage being the most significant factors impacting the score. Technical analysis indicates a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors collectively suggest a high-risk investment with limited upside potential.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) vs. iShares MSCI India ETF (INDA)

Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model

Company DescriptionKrebs Biochemicals & Industries Ltd. (KREBSBIO) is a pharmaceutical company based in India, specializing in the production of active pharmaceutical ingredients (APIs) and intermediates. The company operates in the biotechnology sector, leveraging fermentation and chemical synthesis technologies to manufacture a wide range of products. Its core offerings include APIs for anti-inflammatory, anti-diabetic, cardiovascular, and anti-cholesterol medications, serving both domestic and international markets.
How the Company Makes MoneyKrebs Biochemicals & Industries Ltd. generates revenue primarily through the sale of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company engages in contract manufacturing and custom synthesis services, enabling it to cater to specific client requirements and expand its market reach. Significant revenue streams also arise from its partnerships and collaborations with other pharmaceutical firms, which help in scaling its production capabilities and accessing broader distribution networks. Factors such as regulatory approvals, product quality, and technological advancements in fermentation and synthesis play a crucial role in its earnings.

Krebs Biochemicals & Industries Ltd. Financial Statement Overview

Summary
Krebs Biochemicals & Industries Ltd. faces significant financial challenges, with consistent losses, high leverage, and poor cash flow management. The negative net income, EBIT margins, and unfavorable debt-to-equity ratio highlight financial distress and operational inefficiencies.
Income Statement
10
Very Negative
Krebs Biochemicals & Industries Ltd. has consistently faced challenges in generating profits, with negative net income and EBIT margins over multiple years. The net profit margin and EBIT margin are significantly negative, indicating ongoing operational difficulties. Revenue has been declining, and the gross profit margin is also poor, highlighting inefficiencies in cost management and sales performance.
Balance Sheet
20
Very Negative
The balance sheet reveals a highly leveraged position with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is unfavorable due to the high level of debt relative to equity, and the equity ratio is negative, underscoring the company's risk of insolvency. This presents a significant risk for creditors and investors.
Cash Flow
15
Very Negative
Krebs Biochemicals & Industries Ltd. has struggled with cash flow management, as evidenced by negative free cash flow and operating cash flow across multiple years. The free cash flow to net income ratio is poor, indicating that the company is not effectively converting its earnings into cash. This ongoing cash flow issue poses a challenge for sustaining operations and meeting financial obligations.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue433.12M433.12M504.21M521.34M597.03M386.06M
Gross Profit377.56M377.56M-108.75M97.83M-57.64M-129.90M
EBITDA-143.21M-143.21M-82.73M-151.62M-328.46M-169.63M
Net Income-269.39M-269.39M-197.28M-246.92M-445.27M-283.59M
Balance Sheet
Total Assets1.69B1.69B1.78B1.75B1.90B1.59B
Cash, Cash Equivalents and Short-Term Investments3.38M3.38M1.37M3.72M1.01M10.77M
Total Debt2.12B2.12B2.39B1.83B1.88B1.26B
Total Liabilities3.15B3.15B2.97B2.74B2.65B2.02B
Stockholders Equity-1.46B-1.46B-1.19B-994.62M-750.93M-427.33M
Cash Flow
Free Cash Flow0.00-114.54M-50.23M-355.84M-407.36M-400.81M
Operating Cash Flow0.00-78.91M23.04M-247.13M-172.16M-145.75M
Investing Cash Flow0.00-49.70M-78.17M-126.45M-229.00M-225.49M
Financing Cash Flow0.00128.65M55.64M373.43M395.06M376.61M

Krebs Biochemicals & Industries Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price70.50
Price Trends
50DMA
79.88
Negative
100DMA
79.56
Negative
200DMA
85.35
Negative
Market Momentum
MACD
-2.08
Positive
RSI
34.75
Neutral
STOCH
12.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Negative. The current price of 70.5 is below the 20-day moving average (MA) of 74.91, below the 50-day MA of 79.88, and below the 200-day MA of 85.35, indicating a bearish trend. The MACD of -2.08 indicates Positive momentum. The RSI at 34.75 is Neutral, neither overbought nor oversold. The STOCH value of 12.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KREBSBIO.

Krebs Biochemicals & Industries Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
₹2.41B29.95
2.36%2924.94%
60
Neutral
₹1.70B47.43
-4.74%-41.53%
55
Neutral
₹1.39B19.47
1.35%-14.16%-6.46%
54
Neutral
₹1.31B309.48
15.13%-4518.87%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
39
Underperform
₹1.57B
-31.91%-38.46%
₹1.99B7.67
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
70.50
-12.95
-15.52%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
62.94
-9.33
-12.91%
IN:ALPA
Alpa Laboratories Limited
96.05
-8.25
-7.91%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
104.65
23.65
29.20%
IN:BALPHARMA
Bal Pharma Limited
88.65
-42.33
-32.32%
IN:VAISHALI
Vaishali Pharma Ltd.
12.18
-6.13
-33.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025